글로벌 CRISPR 유전자 편집 시장 – 2031년까지의 산업 동향 및 예측

CRISPR 유전자 편집 시장 분석 및 규모

CRISPR 유전자 편집 시장은 급속한 성장을 경험하고 있으며 생명공학, 의료 및 농업 분야를 변화시킬 태세를 갖추고 있습니다. 이 시장은 주로 유전적 질환, 암 및 기타 질병을 치료하는 혁신적인 치료법에 대한 수요 증가에 의해 주도됩니다. CRISPR 기술은 유전자를 편집하는 정확하고 효율적인 방법을 제공하여 다양한 질병의 치료에 혁명을 일으킬 수 있는 표적 치료법을 개발할 수 있습니다. 농업에서 CRISPR의 적용이 확대되고 있으며, 수확량이 증가하고 해충 및 질병에 대한 저항성이 있는 작물을 개발하는 데 사용하는 것이 시장 성장을 더욱 촉진하고 있습니다.

글로벌 CRISPR 유전자 편집 시장 규모는 2023년에 14억 1,000만 달러로 평가되었으며, 2031년까지 113억 6,000만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 29.80%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

시장 정의

CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats)는 과학자들이 유기체의 DNA를 정확하게 변경할 수 있게 해주는 혁신적인 유전자 편집 기술입니다. 박테리아가 바이러스를 방어하는 데 사용하는 자연적 과정을 기반으로 합니다. CRISPR 기술은 유전학 연구에 혁명을 일으켰으며 유전적 질환을 치료하고, 새로운 치료법을 개발하고, 작물 수확량을 개선할 잠재력이 있습니다.          

CRISPR 유전자 편집 시장 동향

운전자

• 개인화된 의학에 대한 수요 증가  

개인화된 의학은 각 환자의 고유한 유전적 구성을 고려하여 다양한 질병에 대해 보다 집중적이고 효과적인 치료법을 제공하는 것을 목표로 합니다. CRISPR 기술은 게놈에 대한 정확한 수정을 가능하게 하여 질병과 관련된 유전적 돌연변이를 교정함으로써 이 접근 방식에서 중요한 역할을 합니다. 개별 유전적 프로필에 맞게 치료법을 맞춤화하는 이러한 능력은 치료 결과를 개선하고 부작용을 줄임으로써 의료에 혁명을 일으킬 잠재력이 있으며, 의료 실무에서 CRISPR 유전자 편집의 채택이 증가하는 것을 촉진합니다.    

• CRISPR 기술의 급속한 발전

한 가지 주요 발전 분야는 유전체의 특정 영역을 더 정확하게 타겟팅하여 오프타겟 효과의 위험을 줄일 수 있는 보다 정확한 CRISPR 시스템을 개발하는 것입니다. 또한 전달 방법의 개선으로 CRISPR 구성 요소를 세포에 도입하기가 더 쉬워져 유전자 편집의 효율성이 향상되었습니다. 이러한 발전으로 CRISPR 기술의 잠재적 응용 분야가 크게 확장되어 새로운 치료법 개발, 유전자 기능 연구, 유익한 특성을 가진 유전자 변형 생물의 생성을 포함한 다양한 분야에서 귀중한 도구가 되었습니다. 특이성과 효율성의 개선을 포함한 CRISPR 기술의 지속적인 발전이 시장 성장을 촉진하고 있습니다.

기회

• Expansion of Therapeutic Applications  

CRISPR technology has shown promise in treating a wide range of genetic disorders, infectious diseases, and cancer by targeting specific genes associated with these conditions. In the field of genetic disorders, CRISPR has the potential to correct disease-causing mutations, offering a potential cure for genetic diseases that were previously untreatable. In infectious diseases, CRISPR can be used to target and eliminate viral or bacterial DNA, providing a new approach to combating antibiotic-resistant pathogens.  The expansion of CRISPR-based therapeutic applications represents a significant opportunity for market growth.     

• Development of Novel Therapies    

The development of gene therapies that use CRISPR to correct genetic mutations underlying various diseases has shown promise in early clinical trials for conditions such as sickle cell anemia and beta-thalassemia. Another area of innovation is the use of CRISPR in the development of personalized cancer therapies. By targeting specific genetic mutations in a patient's tumor cells, CRISPR can help tailor treatments to individual patients, potentially improving treatment outcomes. CRISPR technology is driving the development of novel therapies that were previously not possible, opening up new opportunities in the pharmaceutical and biotechnology industries.

Restraints/Challenges

• Ethical and Regulatory Challenges        

The ability to make heritable changes to the genome raises complex ethical questions regarding the potential misuse of the technology, the creation of designer babies, and the alteration of future generations' genetic makeup. These concerns have led to calls for strict regulations and guidelines governing the use of CRISPR in human germline editing. In addition, regulatory challenges, such as the need for clear approval processes and oversight mechanisms, further complicate the development and commercialization of CRISPR-based products, creating significant challenges for the market.

• Intellectual Property Disputes

 The CRISPR-Cas9 technology is based on groundbreaking research that has led to the filing of numerous patents by different research groups and institutions. These disputes have resulted in legal battles over patent rights, which could impact the market landscape and slow down the development and commercialization of CRISPR-based products. Ongoing intellectual property disputes over key CRISPR patents represent another challenge for the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In February 2023, Vertex hinted at its launch strategy for the first CRISPR gene editing therapy, pending FDA approval. The therapy, developed in partnership with CRISPR Therapeutics, targets a specific group of patients with severe disease, estimated to be around 32,000 individuals in the U.S. and Europe. These patients are concentrated in specific geographic regions and typically experience frequent vaso-occlusive crises or depend on regular blood transfusions, necessitating multiple hospitalizations annually              
• In March 2021, Setsuro Tech, a Japanese biotech company, secured a patent for CRISPR-Cas9 technology from ERS Genomics, based in Dublin. Setsuro Tech is leveraging this advanced technology to develop animal and cell models, showcasing its commitment to innovative research in the field

CRISPR Gene-Editing Market Scope

The market is segmented on the basis of therapeutic application, application, technology, services, products, and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapeutic Application

• Oncology
• Autoimmune or Inflammatory

Application

• Genome Engineering
• Disease Models
• Functional Genomics
• Others

Technology

• CRISPR or Cas9
• Zinc Finger Nucleases
• Others

Services

• Design Tools
• Plasmid and Vector
• Cas9 and g-RNA
• Delivery System Products
• Others

Products

• GenCrispr or Cas9 kits
• GenCrispr Cas9 Antibodies
• GenCrispr Cas9 Enzymes
• Others

End-Users

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations
• Others

CRISPR Gene-Editing Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, therapeutic application, application, technology, services, products, and end-users as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to substantial investments from biotechnology and pharmaceutical companies. In addition, the region's expanding healthcare infrastructure is expected to enhance market growth during the forecast period further.     

Asia-Pacific is expected to witness significant growth during the forecast period due to the rising per capita income in the region. Moreover, early access to authorized therapies is anticipated to drive market growth in Asia-Pacific in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and CRISPR Gene-Editing Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Applied StemCell (U.S.)
• ACEA BIO (U.S.)
• Synthego (U.S.)
• Thermo Fisher Scientific (U.S.)
• GenScript (China)
• Addgene (U.S.)
• Merck KGaA (Germany)
• Intellia Therapeutics, Inc. (U.S.)
• Cellectis (France)
• Precision Biosciences (U.S.)
• Caribou Biosciences, Inc. (U.S.)
• Transposagen Biopharmaceuticals, Inc. (U.S.)
• OriGene Technologies, Inc. (U.S.)
• 노바티스 AG(스위스)
• 뉴잉글랜드 바이오랩스(미국)
• Rockland Immunochemicals Inc. (미국)
• ToolGen, Inc. (한국)
• TAKARA BIO INC.(일본)
• Agilent Technologies, Inc. (미국)
• Abcam plc (영국)
• CRISPR Therapeutics AG(스위스)

SKU-46288